Photofrin prices near Virginia Beach, VA
Lowest: $99,999.00 Highest: $99,999.00
What is Photofrin?
What is this medicine?
PORFIMER is a light sensitizing drug that is used in photodynamic therapy (PDT). This medicine stays in tumor cells longer than it does in most healthy cells. This targets the tumor cells for laser light therapy. It is used to treat Barrett's esophagus, esophageal cancer, and lung cancer.
This medicine may be used for other purposes; ask your health care provider or pharmacist if you have questions.
How to take Photofrin
How should I use this medicine?
This drug is given as an injection into a vein. It is administered in a hospital or clinic by a specially trained health care professional.
Talk to your pediatrician regarding the use of this medicine in children. Special care may be needed.
Overdosage: If you think you have taken too much of this medicine contact a poison control center or emergency room at once.
NOTE: This medicine is only for you. Do not share this medicine with others.
What should I watch for while using this medicine?
This therapy will cause swelling and pain at the site of the tumor with more secretions and mucus in the lungs or throat. Contact your doctor right away if you have trouble breathing or swallowing. Tell your doctor if your symptoms do not go away or if they get worse.
This medicine will make you more sensitive to light. Sunscreens will NOT protect from this new sensitivity. You must avoid exposing skin and eyes to sunlight and bright indoor lights (unshaded light bulbs at close range) for at least 30 days. This medicine stays in the cells of your skin and eyes for 1 to 3 months. You should continue to expose your body to regular light bulb light. Regular exposure to normal indoor lighting will help to breakdown the medicine in your body. The level of light sensitivity will be different for different areas of the body. After 30 days test your skin sensitivity by getting direct sunlight or bright indoor light on a small area of skin for 10 minutes. If there is no skin reaction, no redness, no swelling, no blisters, within 24 hours, you may begin to spend more time in bright light. If a reaction occurs, wait another 2 weeks before trying again.
Your eyes will be more sensitive to light after taking this medicine. Light from the sun, bright lights, or car headlights may bother your eyes. Wear dark sunglasses for at least 30 days after taking this medicine.
Do not become pregnant while taking this medicine. Women should inform their doctor if they wish to become pregnant or think they might be pregnant. There is a potential for serious side effects to an unborn child. Talk to your health care professional or pharmacist for more information. Do not breast-feed an infant while taking this medicine.
What if I miss a dose of Photofrin?
What if I miss a dose?
It is important not to miss your dose. Call your doctor or health care professional if you are unable to keep an appointment.
Side Effects of Photofrin
What side effects may I notice from receiving this medicine?
Side effects that you should report to your doctor or health care professional as soon as possible:
-allergic reactions like skin rash, itching or hives, swelling of the face, lips, or tongue
-blisters, redness, swelling of skin (similar to a severe sunburn)
-changes in vision
-chest or throat pain
-coughing up or vomiting blood
-dark or bloody stools
-fast, irregular heartbeat
-swelling of the ankles, feet, hands
-unusually high or low blood pressure
-unusually weak or tired
Side effects that usually do not require medical attention (report to your doctor or health care professional if they continue or are bothersome):
-loss of appetite
-sensitive to the sun and bright lights
-stomach gas, upset
This list may not describe all possible side effects. Call your doctor for medical advice about side effects. You may report side effects to FDA at 1-800-FDA-1088.
Interactions with Photofrin
What may interact with this medicine?
-medicines for blood pressure like amlodipine, felodipine, nifedipine
-medicines that treat or prevent blood clots like warfarin, enoxaparin, and dalteparin
-other medicines that may make you sensitive to the sun like phenothiazines, some medicines for diabetes, thiazide diuretics, griseofulvin, tetracyclines, sulfonamide, and fluoroquinolone antibiotics
-steroid medicines like prednisone or cortisone
-vitamins A and E
This list may not describe all possible interactions. Give your health care provider a list of all the medicines, herbs, non-prescription drugs, or dietary supplements you use. Also tell them if you smoke, drink alcohol, or use illegal drugs. Some items may interact with your medicine.
What should I tell my health care provider before I take this medicine?
They need to know if you have any of these conditions:
-esophageal fistulas, varices, or ulcers
-recent or ongoing radiation therapy
-tumors that are growing into major blood vessels
-an unusual or allergic reaction to porfimer, other medicines, foods, dyes, or preservatives
-pregnant or trying to get pregnant
Conditions Commonly Treated by Photofrin
Prescription prices may vary from pharmacy to pharmacy and are subject to change. The pricing estimates given are based on the most recent information available and may change based on when you actually fill your prescription at the pharmacy. The day supply is based upon the average dispensing patterns or the specific drug and strength. The Program, as well as the prices and the list of covered drugs, can be modified at any time without notice.
Blog Posts Related to Photofrin
Are you one of the many people in the United States planning to enjoy a smoke-free 2019? A new year comes with the promise of a clean slate and the opportunity to make resolutions to improve your quality of life, leaving you a healthier, stronger and happier person. A YouGov NY poll conducted last...
The US Food and Drug Administration (FDA) has released the first of two new pieces of draft guidance that may eventually enable e-cigarette manufacturers to apply for regulated drug status for their products.
FDA Commissioner Scott Gottlieb, MD, said there is “no greater impact we can...
Streamlining the process of bringing biosimilars to market is one of the keys to facilitating innovation and reducing healthcare costs, according to US Food and Drug Administration (FDA) Commissioner Scott Gottlieb.
Speaking at the Brookings Institution on the release of the FDA’s...
Fulphila (pegfilgrastim-jmdb) is the first biosimilar to Neulasta (pegfilgrastim) to gain approval from the US Food and Drug Administration (FDA). The Mylan GmbH medicine was approved as a treatment to reduce the risk of infection as suggested by febrile neutropenia (fever caused by a lack of...
Among white and Hispanic people born after 1965, rates of lung cancer are now higher in women than men, according to researchers from the American Cancer Society and National Cancer Institute.
The study, published last month in the New England Journal of Medicine, revealed an overall decline...
The US Food and Drug Administration (FDA) has approved the protein kinase inhibitor Tagrisso (osimertinib) as a first-line treatment option for certain patients with metastatic non-small cell lung carcinoma (NSCLC). Earlier this month, AstraZeneca presented new data from a Phase III FLAURA trial...
The US Food and Drug Administration (FDA) has expanded the approval of Imfinzi (durvalumab) to provide a therapy to slow the progression of cancer in certain patients with non-small cell lung cancer (NSCLC). AstraZeneca first gained accelerated FDA approval for Imfinzi in May 2017.
Imfinzi is an...
More than four in ten (42 percent) of cancer cases in the United States are linked to risk factors associated with cancer, such as smoking, obesity, poor diet, ultraviolet radiation and physical inactivity, according to a new study conducted by the American Cancer Society. The results of the...
Around 49 million American adults were still using tobacco products in 2015, according to new data published by the Centers for Disease Control and Prevention (CDC) and the US Food and Drug Administration’s (FDA) Center for Tobacco Products.
The Morbidity and Mortality Weekly Report...
The US Food and Drug Administration (FDA) has granted breakthrough therapy (BTD) designation to the AstraZeneca drug Tagrisso (osimertinib). It is the sixth such designation granted to AstraZeneca oncology medicine since 2014. Tagrisso received BTD for first-line treatment of patients with...
The US Food & Drug Administration's (FDA) decision to approve a medication to treat patients whose cancer has a specific genetic feature, or biomarker, has been hailed as an "important first" in the fight against the disease. Keytruda (pembrolizumab) is a monoclonal antibody already in use to...
Non-small cell lung cancer (NSCLC) patients have a new treatment available following the US Food & Drug Administration's (FDA's) approval of Alunbrig (brigatinib). The Takeda Pharmaceuticals medication received Accelerated Approval for treatment of patients with anapestic lymphoma...